P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple
cohort study; a multiple dose cycle administration cohort study; and a combination
administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in
patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and
safety study. Rimiducid may be administered as indicated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Poseida Therapeutics, Inc.
Collaborator:
California Institute for Regenerative Medicine (CIRM)